Business Wire

Reply Creative Challenge 2021: With an Idea Developed for easyJet, a Team of Young Students From Politecnico of Milan Wins the Competition

27.7.2021 10:30:00 EEST | Business Wire | Press release

Share

With the project “easyDream”, team Watermelon won the 2021 edition of the Creative Challenge, the largest team-based competition in Europe for students and young creatives and part of the Reply Challenges program.

Launched last May 21st with the online qualification marathon (running 48h), the challenge gathered over 12,000 creative talents (+94% vs. 2020 edition) from 82 countries around the World to focus their creative efforts on nine categories: "Brand Activation", "Brand Experience", "Employer Branding", "Employee Engagement", "Digital Customer Experience", "Digital Gamification", "Fan-base activation", "Innovation Design" and "Social Media".

Spread across over 1,900 teams (+90% vs. 2020 edition), the young talents - with an average age between 14 and 24 - put their skills and personalities into the development of a creative concept based on a real brief created by Reply in collaboration with the Brand Partners of the initiative: AC Milan, Ducati, easyJet, Miele, Mondelez International, Pamela Reif, Sky, Telekom and Tuc,

Nine finalist teams, Jovenhub (for the category Brand Activation powered by Miele), Actontown (for the category Brand Experience powered by Tuc), Creative minds (for the category Employer Branding powered by Sky), Kings & Castles (for the category Employee Engagement powered by Mondelez International), Watermelon (for the category Digital Customer Experience powered by easyJet), Power Up (for the category Digital Gamification powered by Telekom), Cookies accepted (for the category Fan-base Activation powered by AC Milan), Replikate (for the category Innovation Design powered by Pamela Reif) and Creathics (for the category Social Media powered by Ducati), progressed to the final round that took place on July 1st, during which they had the opportunity to exhibit their concepts to an exceptional jury composed of the Art and Creative Directors of Reply agencies (Avvio Reply, Bitmama Reply, Open Reply, Triplesense Reply, WM Reply and Xister Reply) and some of the most renowned marketing and communication professionals of the Brand Partners of the initiative who gave tips and feedbacks on the teams’ work.

Live streamed on Facebook and YouTube, the presentations were judged on a combination of elements and skills as the quality of the presentation, the adherence to the briefs assigned, the originality of the project and the highly quality materials produced. Team Watermelon finished top of the podium, presenting an idea in the Digital Customer Experience category powered by easyJet that leverages on the users’ emotional expectations to choose the next holiday destination.

Team Watermelon, composed by Fedele Cavaliere (22 years old), Andrea De Bernardi (22 years old), Elisa Manzoni (23 years old) and Elio Raineri (23 years old), are all students of Digital and Interaction Design at the Politecnico of Milan University. The team commented the victory: “During the two days of challenge, we had a great time together, answering to a real brief, created by a real and prestigious brand. The possibility to free our creativity has allowed us to have fun and explore new concepts in many ways without constraints, leading our minds to the final result. Despite the short time, we had the chance to create an idea, capable of being shared with others and presented to an international jury, competing with other amazing teams.”

“Watermelon didn’t simply meet the brief – they exceeded it at every opportunity. Their designs employed the perfect balance of creativity, research, and UX design methodology – but on top of that, they produced stunning interactive prototypes, marketing ideas, and a thoroughly entertaining pitch video. What the team managed to pull off in a single weekend is nothing short of amazing!“ commented the jury of the "Digital Customer Experience" cateogy composed by Karina Berzinska, Digital Product Manager easyJet, Alex Black, Lead Product Owner easyJet Holidays and Alex Reekie, Senior Manager WM Reply.

The Creative Challenge is part of the Reply Challenges 2021 competition series organized by Reply for young students, talents and technology enthusiasts to promote the culture of coding and stimulate digital innovation in the fields of creativity, cybersecurity and finance.

To find out more about the Creative Challenge 2021 please visit challenges.reply.com.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye